Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

November 30, 2003

Study Completion Date

October 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

gemcitabine hydrochloride

DRUG

pemetrexed disodium

Trial Locations (22)

32224

Mayo Clinic, Jacksonville

48106

CCOP - Ann Arbor Regional, Ann Arbor

55416

CCOP - Metro-Minnesota, Saint Louis Park

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

CentraCare Health Plaza, Saint Cloud

57104

CCOP - Sioux Community Cancer Consortium, Sioux Falls

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

58201

Altru Health Systems, Grand Forks

58501

Medcenter One Health System, Bismarck

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68106

CCOP - Missouri Valley Cancer Consortium, Omaha

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

43623-3456

CCOP - Toledo Community Hospital, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

15212-4772

Allegheny General Hospital, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00022646 - Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter